Minggu, 17 April 2016

Nano-Technology: New Hopes in Cancer Treatment

Unknown     06.37  No comments

cancer has become a foremost cause of death around the world. Cancer is an extremely complex disease to understand because it entails multiple cellular physiological systems such as cell signaling and apoptosis. However the most cancer treatments are limited to chemotherapy, radiation and surgery.

Even in these scopes, different drawback plays major role shortcoming its affectivity. 99% of chemotherapy does not reach the cancer cells, US National Cancer Institute (OTIR, 2006). Moreover poor drug delivery and residence at the target sites reach o significant complications including multi drug-resistance.

Radiation therapy is also not specific to cancer cells. Most of the normal cells in the body die at 460 C (1080 F) which limited the extent of affectivity of radiation therapy. And most of times surgery is possible if cancer is detected at early stages.

Nanotechnology has the power to offer solutions to these current obstacles in cancer therapies due to its unique size (1-100 nm) and large surface to volume ratios. Currently, lots of research is going on to design novel nanodevices capable of detecting cancer at its earliest stages, pinpointing its location in the body and delivering anti-cancer drugs specifically to malignant cells. According to OTIR:

Unknown


Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Ut odio. Nam sed est. Nam a risus et est iaculis adipiscing. Vestibulum ante ipsum faucibus luctus et ultrices.
View all posts by Naveed →

0 komentar :

About U.S. Pharma Corporation

U.S. Pharma Corporation is headquartered in New Jersey but has research sites in Germany, France, the United Kingdong, Switzerland, and Australia. Research and development of new pharmaceuticals is key to ongoing profits, and U.S. Pharma researches and tests thousands of possible drugs. The company’s researchers need to share information with others within and outside the company, including the U.S. Food and Drug Administration, the World Health Organization, and the International Federation of Pharmaceutical Manufactureres & Associations. Also critical is Access to health information sites, such as the U.S. National Library of Medicine and to industry conferences and professional journals.